DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0054381 A1 Letts (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0054381 A1 Letts (43) Pub US 2009.0054381A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0054381 A1 Letts (43) Pub. Date: Feb. 26, 2009 (54) METHODS FORTREATING RESPIRATORY Related U.S. Application Data DSORDERS (60) Provisional application No. 60/722,961, filed on Oct. 4, 2005. (75) Inventor: L. Gordon Letts, Dover, MA (US) Publication Classification Correspondence Address: (51) Int. Cl. WILMERHALEANTROMED A63L/50 (2006.01) 1875 PENNSYLVANIAAVE, NW A6II 3/56 (2006.01) WASHINGTON, DC 20006 (US) A6IP 9/00 (2006.01) A6IP II/00 (2006.01) (73) Assignee: NitroMed, Inc., Lexington, MA (52) U.S. Cl. ......................................... 514/171; 514/247 (US) (57) ABSTRACT The invention provides methods for treating respiratory dis (21) Appl. No.: 12/088,922 orders in a patient in need thereof comprising administering an effective amount of (i) at least one hydralazine compound (22) PCT Filed: Oct. 4, 2006 or a pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at (86). PCT No.: PCT/USO6/38965 least one therapeutic agent. The hydralazine compound may be hydralazine hydrochloride. The respiratory disorders may S371 (c)(1), be chronic obstructive pulmonary disease, pulmonary hyper (2), (4) Date: Jul. 11, 2008 tension, emphysema, asthma, cystic fibrosis and bronchitis. US 2009/0054381 A1 Feb. 26, 2009 METHODS FOR TREATING RESPRATORY obstructive pulmonary disease, pulmonary hypertension, DISORDERS emphysema, asthma, cystic fibrosis and bronchitis. In these embodiments of the invention, the methods can involve (i) RELATED APPLICATIONS administering the hydralazine compound or a pharmaceuti 0001. This application claims priority under 35 USC S 119 cally acceptable salt thereof, and at least one of isosorbide to U.S. application Ser. No. 60/722,961 filed Oct. 4, 2005, the dinitrate and/or isosorbide mononitrate, or (ii) administering disclosure of which is incorporated by reference herein in its the hydralazine compound or a pharmaceutically acceptable entirety. salt thereof, at least one of isosorbide dinitrate and/or isosor bide mononitrate, and therapeutic agents. The hydralazine FIELD OF THE INVENTION compound group, isosorbide dinitrate and/or isosorbide mononitrate and/or therapeutic agents can be administered 0002 The invention provides methods for treating respi separately or as components of the same composition in one ratory disorders in a patient in need thereof comprising or more pharmaceutically acceptable carriers. administering an effective amount of (i) at least one hydrala 0005. The invention provides methods for treating respi Zine compound or a pharmaceutically acceptable salt thereof, ratory disorders in a patient in need thereof comprising (ii) isosorbide dinitrate and/or isosorbide mononitrate, and administering to the patient an effective amount of hydrala (iii) optionally at least one therapeutic agent. The hydralazine zine hydrochloride and isosorbide dinitrate. The methods can compound may be hydralazine hydrochloride. The respira optionally further comprise the administration of at least one tory disorders may be chronic obstructive pulmonary disease, therapeutic agent, such as, for example, antimicrobial com pulmonary hypertension, emphysema, asthma, cystic fibrosis pounds, aldosterone antagonists, alpha-adrenergic receptor and bronchitis. antagonists, f-adrenergic agonists, anti-allergic compounds, antidiabetic compounds, anti-hyperlipidemic drugs, antitus BACKGROUND OF THE INVENTION sive compounds, angiotensin II antagonists, angiotensin-con 0003. The incidence and prevalence of respiratory dis Verting enzyme (ACE) inhibitors, antioxidants, antithrom eases and disorders has increased over the past decade. Also botic and vasodilator drugs, B-adrenergic antagonists, there has been reported an alarming increase in mortality bronchodilators, calcium channel blockers, diuretics, endot associated with respiratory disorders. Current methods for helin antagonists, expectorants, hydralazine compounds, H. treating these disorders are not optimal, as they require fre receptor antagonists, neutral endopeptidase inhibitors, non quent and repeated administration of the appropriate drugs, steroidal antiinflammatory compounds (NSAIDs), phos resulting in issues of compliance. There is a need in the art for phodiesterase inhibitors, potassium channel blockers, plate new and more effective compositions and methods for treat let reducing agents, proton pump inhibitors, renin inhibitors, ingrespiratory disorders. The invention is directed to these, as selective cyclooxygenase-2 (COX-2) inhibitors, steroids, and well as other, important ends. combinations of two or more thereof. In another embodiment the at least one therapeutic agent is selected from the group SUMMARY OF THE INVENTION consisting of antimicrobial compounds, B-adrenergic ago nist, an anti-allergic compound, an antitussive compound, an 0004. The invention provides methods for treating respi antioxidant, a bronchodilator, an expectorant, a nonsteroidal ratory disorders in a patient in need thereof comprising antiinflammatory compound (NSAIDs), a phosphodiesterase administering to the patient an effective amount of (i) a inhibitor, a selective cyclooxygenase-2 (COX-2) inhibitor hydralazine compound or a pharmaceutically acceptable salt and a steroid. In one embodiment the respiratory disorder is thereof, (ii) isosorbide dinitrate and/or isosorbide mononi chronic obstructive pulmonary disease, pulmonary hyperten trate, and (iii) optionally at least one therapeutic agent. In one Sion, emphysema, asthma, cystic fibrosis and bronchitis. In embodiment the therapeutic agents include, but are not lim these embodiments of the invention, the methods can involve ited to, antimicrobial compounds, aldosterone antagonists, (i) administering the hydralazine hydrochloride and isosor cc-adrenergic receptor antagonists, f-adrenergic agonists, bide dinitrate, or (ii) administering the hydralazine hydro anti-allergic compounds, antidiabetic compounds, anti-hy chloride, isosorbide dinitrate and therapeutic agents. The perlipidemic drugs, antitussive compounds, angiotensin II hydralazine hydrochloride, isosorbide dinitrate and/or thera antagonists, angiotensin-converting enzyme (ACE) inhibi peutic agents can be administered separately or as compo tors, antioxidants, antithrombotic and vasodilator drugs, nents of the same composition in one or more pharmaceuti B-adrenergic antagonists, bronchodilators, calcium channel cally acceptable carriers. blockers, diuretics, endothelin antagonists, expectorants, hydralazine compounds, H receptor antagonists, neutral 0006. These and other aspects of the invention are endopeptidase inhibitors, nonsteroidal antiinflammatory described in detail herein. compounds (NSAIDs), phosphodiesterase inhibitors, potas sium channel blockers, platelet reducing agents, proton pump DETAILED DESCRIPTION OF THE INVENTION inhibitors, renin inhibitors, selective cyclooxygenase-2 0007 As used throughout the disclosure, the following (COX-2) inhibitors, steroids, and combinations of two or terms, unless otherwise indicated, shall be understood to have more thereof. In another embodiment the at least one thera the following meanings. peutic agent is selected from the group consisting of an anti 0008 “Patient” refers to animals, preferably mammals, microbial compound, a B-adrenergic agonist, an anti-allergic most preferably humans, and includes males and females. compound, an antitussive compound, an antioxidant, a bron 0009 “Effective amount refers to the amount of the com chodilator, an expectorant, a nonsteroidal antiinflammatory pound and/or composition that is necessary to achieve its compound (NSAIDs), a phosphodiesterase inhibitor, a selec intended purpose. tive cyclooxygenase-2 (COX-2) inhibitor and a steroid. In 0010) “Respiratory disorder” refers to any respiratory dis another embodiment the respiratory disorders is chronic ease or respiratory disorder. Such as, for example, chronic US 2009/0054381 A1 Feb. 26, 2009 obstructive pulmonary disease, pulmonary hypertension, tives thereof, peptides, including di- and tri-peptides, and emphysema, asthma, cystic fibrosis, bronchitis, acute pulmo antibodies to ACE which intervene in the renin-angiotensin nary vasoconstriction, pneumonia, traumatic injury, aspira system by inhibiting the activity of ACE thereby reducing or tion or inhalation injury, fat embolism in the lung, acidosis, eliminating the formation of the pressor Substance angio inflammation of the lung, adult respiratory distress syndrome, tensin II. acute pulmonary edema, acute mountain sickness, post car 0016 “Angiotensin II antagonists' refers to compounds diac Surgery, pulmonary hypertension, persistent pulmonary which interfere with the function, synthesis or catabolism of hypertension of the newborn, perinatal aspiration syndrome, angiotensin II. Angiotensin II antagonists include peptide hyaline membrane disease, acute pulmonary thromboembo compounds and non-peptide compounds, including, but not lism, heparin-protamine reactions, sepsis, status asthmaticus, limited to, angiotensin II antagonists, angiotensin II receptor hypoxia, bronchopulmonary dysplasia, chronic pulmonary antagonists, agents that activate the catabolism of angiotensin thromboembolism, idiopathic pulmonary hypertension, pri II, and agents that prevent the synthesis of angiotensin I from mary pulmonary hypertension, chronic hypoxia, Sarcoidosis, angiotensin II. The renin-angiotensin System is involved in
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,784,177 B2 Cohn Et Al
    USOO6784177B2 (12) United States Patent (10) Patent No.: US 6,784,177 B2 Cohn et al. (45) Date of Patent: Aug. 31, 2004 (54) METHODS USING HYDRALAZINE Massie et al., The American Journal of Cardiology, COMPOUNDS AND SOSORBIDE 40:794-801 (1977). DINTRATE OR ISOSORBIDE Kaplan et al., Annals of Internal Medicine, 84:639-645 MONONTRATE (1976). Bauer et al., Circulation, 84(1):35-39 (1991). (75) Inventors: Jay N. Cohn, Minneapolis, MN (US); The SOLVD Investigators, The New England Journal of Medicine, 327(10):685–691 (1992). Peter Carson, Chevy Chase, MD (US) Ziesche et al., Circulation, 87(6):VI56-VI64 (1993). Rector et al., Circulation, 87(6):VI71-VI77 (1993). (73) Assignee: Nitro Med, Inc., Bedford, MA (US) Carson et al., Journal of Cardiac Failure, 5(3):178-187 (Sep. 10, 1999). (*) Notice: Subject to any disclaimer, the term of this Dries et al, The New England Journal of Medicine, patent is extended or adjusted under 35 340(8):609-616 (Feb. 25, 1999). U.S.C. 154(b) by 18 days. Freedman et al, Drugs, 54 (Supplement 3):41-50 (1997). Sherman et al., Cardiologia, 42(2):177-187 (1997). (21) Appl. No.: 10/210,113 Biegelson et al., Coronary Artery Disease, 10:241-256 (1999). (22) Filed: Aug. 2, 2002 Rudd et al, Am. J. Physiol., 277(46):H732–H739 (1999). (65) Prior Publication Data Hammerman et al, Am. J. Physiol., 277(46):H1579–1592 (1999). US 2004/0023967 A1 Feb. 5, 2004 LoScalzo et al., Transactions of the American and Climato logical ASS., 111:158-163 (2000).
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Interactions Between Antihypertensive Drugs and Food B
    11. INTERACTIONS:01. Interacción 29/11/12 14:38 Página 1866 Nutr Hosp. 2012;27(5):1866-1875 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Interactions between antihypertensive drugs and food B. Jáuregui-Garrido1 and I. Jáuregui-Lobera2 1Department of Cardiology. University Hospital Virgen del Rocío. Seville. Spain. 2Bromatology and Nutrition. Pablo de Olavide University. Seville. Spain. Abstract INTERACCIONES ENTRE FÁRMACOS ANTIHIPERTENSIVOS Y ALIMENTOS Objective: A drug interaction is defined as any alter- ation, pharmacokinetics and/or pharmacodynamics, Resumen produced by different substances, other drug treatments, dietary factors and habits such as drinking and smoking. Objetivo: la interacción de medicamentos se define como These interactions can affect the antihypertensive drugs, cualquier alteración, farmacocinética y/o farmacodiná- altering their therapeutic efficacy and causing toxic mica, producida por diferentes sustancias, otros tratamien- effects. The aim of this study was to conduct a review of tos, factores dietéticos y hábitos como beber y fumar. Estas available data about interactions between antihyperten- interacciones pueden afectar a los fármacos antihipertensi- sive agents and food. vos, alterando su eficacia terapéutica y causando efectos Methods: The purpose of this review was to report an tóxicos. El objetivo de este estudio fue realizar una revisión update of main findings with respect to the interactions de los datos disponibles acerca de las interacciones entre los between food and antihypertensive drugs
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,635,273 B1 Loscalz0 Et Al
    USOO6635273B1 (12) United States Patent (10) Patent No.: US 6,635,273 B1 LOScalZ0 et al. (45) Date of Patent: Oct. 21, 2003 (54) METHODS OF TREATING VASCULAR Dries et al, The New England Journal of Medicine, DISEASES CHARACTERIZED BY NITRIC 340(8):609-616 (Feb. 25, 1999). OXDE INSUFFICIENCY Freedman et al, Drugs, 54(Supp. 3):41-50 (1997). Sherman et al., Cardiologia, 42(2):177-187 (1997). (75) Inventors: Joseph Loscalzo, Dover, MA (US); Biegelson et al., Coronary Artery Disease, 10:241-256 Joseph A. Vita, Hingham, MA (US); (1999). Michael D. Loberg, Boston, MA (US); Rudd et al, Am. J. Physiol., 277(46):H732–H739 (1999). Manuel Worcel, Boston, MA (US) Hammerman et al, Am. J. Physiol., 277(46):H1579-H1592 (1999). (73) Assignees: Trustees of Boston University, Boston, LoScalzo et al., Transactions of the American and Climato MA (US); NitroMed, Inc., Bedford, logical ASS., 111:158-163 (2000). MA (US) Cohn et al, The New England Journal of Medicine, 325(5):303-310 (1991). (*) Notice: Subject to any disclaimer, the term of this Cohn et al, The New England Journal of Medicine , patent is extended or adjusted under 35 314(24): 1547–1552 (1986). U.S.C. 154(b) by 0 days. Carson et al., Circulation, Supplement I, 92(8):I31-I32, Abstract No. 0145 (1995). (21) Appl. No.: 09/697,317 (List continued on next page.) (22) Filed: Oct. 27, 2000 Primary Examiner-Jon P. Weber Related U.S. Application Data ASSistant Examiner-Kalash C. Srivastava (60) Provisional application No. 60/179,020, filed on Jan.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • WO 2010/040188 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 15 April 2010 (15.04.2010) WO 2010/040188 Al (51) International Patent Classification: (74) Agents: TOZER, Ramon, D. et al; Davies Collison A61K 47/48 (2006.01) A61K 47/34 (2006.01) Cave, 1 Nicholson Street, Melbourne, Victoria 3000 A61K 31/19 (2006.01) C08G 71/04 (2006.01) (AU). C08G 67/04 (2006.01) A61K 31/13 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 31/045 (2006.01) C08G 63/02 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, PCT/AU2009/001342 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 9 October 2009 (09.10.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (25) Filing Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (30) Priority Data: TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 2008905263 10 October 2008 (10.10.2008) AU (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): THE kind of regional protection available): ARIPO (BW, GH, BIONIC EAR INSTITUTE [AU/AU]; 384 Albert GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, Street, East Melbourne, Victoria 3002 (AU).
    [Show full text]
  • Essential Hypertension J.J.M.L
    Br. J. clin. Pharmac. (1983), 16, 39-44 EFFECTS OF INTRAVENOUS ENDRALAZINE IN ESSENTIAL HYPERTENSION J.J.M.L. HOFFMANNI"*, TH. THIEN2 & A. VAN 'T LAAR2 'Department of Experimental and Chemical Endocrinology and 2Division of General Internal Medicine, Department of Medicine, St Radboud Hospital, Nijmegen, The Netherlands 1 The effects of endralazine, administered intravenously, on blood pressure, heart rate, forearm blood flow, plasma renin activity, aldosterone, adrenaline and noradrenaline were studied in five patients with essential hypertension. 2 Endralazine reduced peripheral vascular resistance, resulting in decrease in mean arterial pressure from 141 to 116 mm Hg and increase in heart rate from 67 to 92 beats/min. 3 Plasma renin activity, adrenaline and noradrenaline increased significantly after endralazine infusion. 4 All effects observed are consistent with endralazine acting as a peripheral vasodilating drug. Introduction Endralazine (BQ 22-708) is a new antilhypertensive Another important difference between both drugs drug, which chemically and pharrniacologically is their major route of metabolism. After oral resembles hydralazine; endralazine is a substituted administration to fast acetylators, hydralazine is hydrazinopyridazine and hydralazine is;a hydrazino- mainly converted by acetylation of its hydrazino- derivative of phtalazine (Figure 1). Both drugs act as moiety, while in slow acetylators hydralazine-pyruvic peripheral vasodilators by direct relaxatioIn of vascular acid hydrazone is the major metabolite (Reece et al., smooth muscle, especially of the resistaince vessels. 1980). So, the patient's acetylator phenotype causes Besides the close relationship, the drugs (display some appreciable inter-individual variation in metabolic differences. On equal weight-basis enidralazine is half-life. Since the major pathway of endralazine about five times more potent than hydrzalazine, thus metabolism is accounted for by hydrazone formation allowing lower dosages.
    [Show full text]
  • Redalyc.Interactions Between Antihypertensive Drugs and Food
    Nutrición Hospitalaria ISSN: 0212-1611 info@nutriciónhospitalaria.com Grupo Aula Médica España Jáuregui-Garrido, B.; Jáuregui-Lobera, I. Interactions between antihypertensive drugs and food Nutrición Hospitalaria, vol. 27, núm. 6, noviembre-diciembre, 2012, pp. 1866-1875 Grupo Aula Médica Madrid, España Available in: http://www.redalyc.org/articulo.oa?id=309226791011 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative 11. INTERACTIONS:01. Interacción 29/11/12 14:38 Página 1866 Nutr Hosp. 2012;27(5):1866-1875 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Interactions between antihypertensive drugs and food B. Jáuregui-Garrido1 and I. Jáuregui-Lobera2 1Department of Cardiology. University Hospital Virgen del Rocío. Seville. Spain. 2Bromatology and Nutrition. Pablo de Olavide University. Seville. Spain. Abstract INTERACCIONES ENTRE FÁRMACOS ANTIHIPERTENSIVOS Y ALIMENTOS Objective: A drug interaction is defined as any alter- ation, pharmacokinetics and/or pharmacodynamics, Resumen produced by different substances, other drug treatments, dietary factors and habits such as drinking and smoking. Objetivo: la interacción de medicamentos se define como These interactions can affect the antihypertensive drugs, cualquier alteración, farmacocinética y/o farmacodiná- altering their therapeutic efficacy and causing toxic mica, producida por diferentes sustancias, otros tratamien- effects. The aim of this study was to conduct a review of tos, factores dietéticos y hábitos como beber y fumar. Estas available data about interactions between antihyperten- interacciones pueden afectar a los fármacos antihipertensi- sive agents and food.
    [Show full text]